Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a …
J Rocha, AG Aprikian, M Vanhuyse, FL Cury… - … Open Access Journal, 2017 - cmajopen.ca
Background: Abiraterone acetate was introduced in Quebec in 2012 for the treatment of
metastatic castration-resistant prostate cancer (mCRPC) in patients who had received …
metastatic castration-resistant prostate cancer (mCRPC) in patients who had received …
Abiraterone acetate versus docetaxel for metastatic castration-resistant prostate cancer: a cohort study within the French nationwide claims database
NH Thurin, M Rouyer, J Jové… - Expert Review of …, 2022 - Taylor & Francis
Objectives To conduct the direct comparison of abiraterone acetate and docetaxel for first-
line treatment of metastatic castration-resistant prostate cancer (mCRPC) in real-life settings …
line treatment of metastatic castration-resistant prostate cancer (mCRPC) in real-life settings …
Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program
C Van Praet, S Rottey, F Van Hende, G Pelgrims… - … Oncology: Seminars and …, 2016 - Elsevier
Background Abiraterone acetate (AA) is licensed for treating metastatic castration-resistant
prostate cancer (mCRPC). Real-world data on oncological outcome after AA are scarce. The …
prostate cancer (mCRPC). Real-world data on oncological outcome after AA are scarce. The …
[HTML][HTML] Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer
AIM: To study the efficacy and safety of abiraterone in patients with and without prior
chemotherapy. METHODS: The databases including PubMed and abstracts presented at the …
chemotherapy. METHODS: The databases including PubMed and abstracts presented at the …
A description of real-world treatment with abiraterone acetate in metastatic castration-resistant prostate cancer patients in the post-chemotherapy setting in France and …
L Dearden, P Musingarimi, N Shalet… - Value in …, 2015 - valueinhealthjournal.com
Objectives In the COU-AA-301 trial, abiraterone acetate with low-dose prednisone (AA) was
found to extend survival in metastatic castrate resistant prostate cancer (mCRPC) patients …
found to extend survival in metastatic castrate resistant prostate cancer (mCRPC) patients …
Which factors predict overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate post-docetaxel?
C Van Praet, S Rottey, F Van Hende, G Pelgrims… - Clinical Genitourinary …, 2017 - Elsevier
Background Abiraterone acetate (AA) increases overall survival (OS) in patients with
metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel …
metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel …
Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer
A Shivji, R Ali, S North, M Sawyer… - Journal of Oncology …, 2019 - journals.sagepub.com
Objectives The COU-AA-301 trial demonstrated that in men with metastatic castrate-resistant
prostate cancer using abiraterone post-docetaxel increased overall survival. This study aims …
prostate cancer using abiraterone post-docetaxel increased overall survival. This study aims …
[HTML][HTML] A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer
R Clayton, J Wu, DY Heng, SA North… - Canadian Urological …, 2014 - ncbi.nlm.nih.gov
Methods: Consecutive patients with mCRPC who received abiraterone post-docetaxel were
identified using centralized pharmacy records. These patients came from 5 Canadian tertiary …
identified using centralized pharmacy records. These patients came from 5 Canadian tertiary …
Clinical benefit of docetaxel or enzalutamide after progression on first-line abiraterone acetate and prednisone in men with metastatic castration resistant prostate …
e16031 Background: Abiraterone acetate (AA) has demonstrated survival benefit in the pre-
chemotherapy setting for patients (pts) with mCRPC, now with widespread clinical use …
chemotherapy setting for patients (pts) with mCRPC, now with widespread clinical use …
[HTML][HTML] Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer: post hoc analysis …
JS de Bono, MR Smith, F Saad, DE Rathkopf… - European urology, 2017 - Elsevier
Background Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC)
have changed substantially in the last few years. In trial COU-AA-302 (chemotherapy-naïve …
have changed substantially in the last few years. In trial COU-AA-302 (chemotherapy-naïve …
Related searches
- abiraterone acetate docetaxel chemotherapy
- prostate cancer docetaxel chemotherapy
- abiraterone acetate prostate cancer
- survival of patients docetaxel chemotherapy
- abiraterone acetate survival of patients
- prostate cancer survival of patients
- prostate cancer cou aa
- abiraterone acetate clinical benefit
- abiraterone acetate cou aa
- prostate cancer clinical benefit
- abiraterone acetate claims database
- prostate cancer claims database
- prostate cancer world evidence
- abiraterone acetate prednisone in men
- abiraterone acetate multicentre analysis
- abiraterone acetate performance status
